Literature DB >> 18665014

Investigation and characterization of the duct cell-enriching process during serum-free suspension and monolayer culture using the human exocrine pancreas fraction.

Tino Klein1, Yves Heremans, Harry Heimberg, Daniel Pipeleers, Ole D Madsen, Palle Serup, R Scott Heller.   

Abstract

OBJECTIVES: We aimed to characterize a serum-free culture system resulting in highly enriched duct cells from human exocrine pancreas. In addition, we tested the effect of vascular endothelial growth factor (VEGF) on endothelial cell proliferation and endocrine differentiation of the duct cells.
METHODS: The exocrine pellet fraction was cultivated in suspension followed by monolayer culture. Time course analysis of multiple acinar and duct cell markers was performed using reverse transcription-polymerase chain reaction and immunocytochemistry. The effects of VEGF and placental growth factor on the quantities of endothelial, duct, and endocrine cells and fibroblasts were investigated using computerized imaging analysis.
RESULTS: Suspension culture of the exocrine material efficiently enriched the cultures for duct cells. Frequent acinar cell death as well as cell selective adherence of acinar cells to the culture dish was the underlying cause of the enrichment. Confocal microscopy demonstrated the virtual absence of cells coexpressing duct cell- and acinar cell-specific markers. The endothelial immunoreactivity of the suspension culture system could be increased 2-fold by VEGF treatment, yet no effect was observed on endocrine cell numbers.
CONCLUSIONS: We have characterized a serum-free in vitro culture system to enrich human duct cells and further show that the contribution of acinoductal transdifferentiation to the enrichment of duct cells is negligible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18665014     DOI: 10.1097/MPA.0b013e3181816547

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells.

Authors:  Weidong Zhou; Michela Capello; Claudia Fredolini; Leda Racanicchi; Lorenzo Piemonti; Lance A Liotta; Francesco Novelli; Emanuel F Petricoin
Journal:  J Proteome Res       Date:  2011-11-17       Impact factor: 4.466

2.  Paracrine Secretion of Transforming Growth Factor β by Ductal Cells Promotes Acinar-to-Ductal Metaplasia in Cultured Human Exocrine Pancreas Tissues.

Authors:  Naoki Akanuma; Jun Liu; Geou-Yarh Liou; Xue Yin; Kaitlyn R Bejar; Chengyang Liu; Lu-Zhe Sun; Peter Storz; Pei Wang
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

3.  Purified human pancreatic duct cell culture conditions defined by serum-free high-content growth factor screening.

Authors:  Corinne A Hoesli; James D Johnson; James M Piret
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

4.  Reprogramming of human pancreatic exocrine cells to β-like cells.

Authors:  M Lemper; G Leuckx; Y Heremans; M S German; H Heimberg; L Bouwens; L Baeyens
Journal:  Cell Death Differ       Date:  2014-12-05       Impact factor: 15.828

5.  TGF-β1 promotes acinar to ductal metaplasia of human pancreatic acinar cells.

Authors:  Jun Liu; Naoki Akanuma; Chengyang Liu; Ali Naji; Glenn A Halff; William K Washburn; Luzhe Sun; Pei Wang
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

6.  FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer.

Authors:  S Chen; J Huang; Z Liu; Q Liang; N Zhang; Y Jin
Journal:  Oncogenesis       Date:  2017-03-13       Impact factor: 7.485

7.  miR-204 is associated with an endocrine phenotype in human pancreatic islets but does not regulate the insulin mRNA through MAFA.

Authors:  Ilaria Marzinotto; Silvia Pellegrini; Cristina Brigatti; Rita Nano; Raffaella Melzi; Alessia Mercalli; Daniela Liberati; Valeria Sordi; Maurizio Ferrari; Massimo Falconi; Claudio Doglioni; Philippe Ravassard; Lorenzo Piemonti; Vito Lampasona
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.